Kairos Pharma Ltd’s recent filing unveils that its VP of Research and Development Murali Ramachandran acquired Company’s shares for reported $318.0 on Nov 25 ’24. In the deal valued at $1.59 per share,200 shares were bought. As a result of this transaction, Murali Ramachandran now holds 133,057 shares worth roughly $ 0.18 million.
Then, Samuelson Doug bought 2,500 shares, generating $3,750 in total proceeds. Upon buying the shares at $1.50, the Chief Financial Officer now owns 60,796 shares.
Before that, Yu John S bought 4,000 shares. Kairos Pharma Ltd shares valued at $5,760 were divested by the CEO and Chairman at a price of $1.44 per share. As a result of the transaction, Yu John S now holds 5,341,837 shares, worth roughly $7.32 million.
Price Performance Review of KAPA
On Friday, Kairos Pharma Ltd [AMEX:KAPA] saw its stock fall -5.52% to $1.37. Over the last five days, the stock has lost -0.72%. Kairos Pharma Ltd shares have fallen nearly -9.87% since the year began.
Levels Of Support And Resistance For KAPA Stock
The 24-hour chart illustrates a support level at 1.2700, which if violated will result in even more drops to 1.1700. On the upside, there is a resistance level at 1.5200. A further resistance level may holdings at 1.6700. The Relative Strength Index (RSI) on the 14-day chart is 45.59, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0674, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.71%. Stochastics %K at 15.05% indicates the stock is a buying.
How much short interest is there in Kairos Pharma Ltd?
A steep rise in short interest was recorded in Kairos Pharma Ltd stocks on 2025-01-31, growing by 0.34 million shares to a total of 0.34 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-31 was 6937.0 shares. There was a rise of 97.99%, which implies that there is a positive sentiment for the stock.
